Re: RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT
posted on
Jan 08, 2018 06:03PM
Tada
I agree on that point, however, payment of the BOM trial expenses in Israel relieves Resverlogix of the liability, whatever that is, or if RVX has already paid the amount they may recieve reimbursement. More importantly, Medison is an organization that can quickly get the drug into the pipeline and on the street generating future revenues.